Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of hCRF and derivatives thereof in preparing medicament for treating Guillain Barre syndrome

A kind of derivative and syndrome technology, applied in the application field of hCRF and its derivatives in the preparation of medicine for treating Guillain-Barre syndrome

Inactive Publication Date: 2009-08-12
SHANDONG UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In the prior art, there have been studies on the use of hCRF for the treatment of cerebral edema, but there have been no studies and reports on the use of hCRF and its derivatives for the preparation of drugs for the treatment of Guillain-Barré syndrome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of hCRF and derivatives thereof in preparing medicament for treating Guillain Barre syndrome
  • Applications of hCRF and derivatives thereof in preparing medicament for treating Guillain Barre syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: Effect of hCRF on Respiration of Rabbits

[0019] 20 New Zealand big-eared white rabbits, aged 6-12 months, weighing 3-4kg. They were randomly divided into two groups, 10 in each group. The control group was given 2 ml of 0.9% normal saline, and the test group was given intravenous injection of hCRF 4 μg / kg. hCRF was dissolved in 2 ml sterile saline before administration. Ventilation (respiratory rate and tidal volume) was measured continuously with a pneumotachometer. The respiratory rate and tidal volume were measured after the respiration of animals in each group reached a steady state, and the measurement period was 40 minutes. The experimental results were compared and analyzed by T test, and P<0.05 was considered significant difference, the results are shown in Table 1.

[0020] Table 1 Effect of hCRF on the respiratory rate and tidal volume of rabbits

[0021]

[0022] * Compared with the control group, P<0.01.

[0023] From the above experim...

Embodiment 2

[0024] Embodiment 2: Mechanism research of hCRF respiratory excitatory effect

[0025] Rabbits were anesthetized with urethane, the vagus nerve was cut off, paralyzed, and mechanically ventilated. hCRF was injected via the fourth ventricle. Record the changes of the neuron tidal volume nVt. An increase in nVt was found, but no effect on expiratory phase duration. The microinjection method was used to inject hCRF into the ventral side of the parabrachial region of the pons, and the expiratory state was recorded. It was found that both nVt and respiratory rate decreased. The effect of hCRF was not significantly affected after ganglion conduction was blocked with tetrachloroindoleamine.

[0026] The above results indicated that hCRF may regulate respiratory movement through the central nervous system and play a respiratory excitatory role.

Embodiment 3

[0027] Example 3: Pharmacodynamic study of hCRF on Guillain-Barré syndrome model animals

[0028] Bear hunting dogs, 8, weighing 28-33kg, male or female. They were randomly divided into two groups, 4 rats in each group. Animals in each group were anesthetized by intravenous injection of ketamine at a dose of 5 mg / kg, and subcutaneously injected with 2 ml of saliva secretion from the bear. Respiratory rate and tidal volume were measured continuously with a pneumotachometer. The control group was given 2ml of 0.9% normal saline, the experimental group was given 5μg / kg hCRF, and hCRF was dissolved in 2ml of sterile normal saline before administration. Both the placebo and the medicine were administered immediately after the subcutaneous injection of the saliva secretion of the bear. The respiratory rate and tidal volume were measured on the 0, 2, 4, 8, 16, and 32 days after the bear dogs woke up. At the same time, blood samples were collected from the hindlimb arteries with a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel application of hCRF and derivatives thereof in drug production, namely, application of hCRF and derivatives thereof in preparing medicines for treating Guillain Barre syndrome. The effective dose is 1-100 mug / kg weight, preferably 2-10 mug / kg weight. Experiments by the inventor prove that the hCRF and derivatives thereof are highly effective respiratory stimulants, which play an obvious role in improving respiration function of the Guillain Barre syndrome. Compared with the method to assist respiration by a breathing machine, the application of the invention can not only maintain and improve ciliary movement function, reduce respiratory tract sputum retention and atelectasis caused by secretion substance vent clog and reduce chances of increasing respiratory tract infection.

Description

technical field [0001] The invention relates to the application of hCRF and its derivatives in the preparation of medicines for treating Guillain-Barré syndrome. Background technique [0002] Guillian-Barre Syndrome (Guillian-Barre Syndrome), also known as acute idiopathic polyneuritis or symmetrical polyneuritis, is a common demyelinating disease of spinal nerves and peripheral nerves. It was named after the first report, and clinically manifested as progressive ascending symmetrical paralysis, quadriplegia, and varying degrees of sensory impairment. Patients with acute or subacute clinical course, most can recover completely, a few severe cases can cause fatal respiratory paralysis and bilateral facial paralysis. [0003] Domestic literature reports that the mortality rate of Guillain-Barré syndrome is 14%-42% (Bai Fayi, Wang Weiping, etc. 1287 backward analysis of Guillain-Barré syndrome (abstract). Chinese Journal of Neuropsychiatry. 1992: (1): 30 .). Among them, vent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K47/48A61P25/00A61K47/60
Inventor 厉保秋
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com